Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1

MicroRNA-135b acts as a tumor promoter by targeting the hypoxia-inducible factor pathway in genetically defined mouse model of head and neck squamous cell carcinoma

(2013) Lu Zhang et al.   CANCER LETTERS

Hypoxia inducible factor pathway inhibitors as anticancer therapeutics

(2013) Sarah K Burroughs et al.   Future Medicinal Chemistry

Exosomes Derived from Hypoxic Leukemia Cells Enhance Tube Formation in Endothelial Cells

(2013) Hiroko Tadokoro et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction

(2013) P Storti et al.   LEUKEMIA

The hypoxia target adrenomedullin is aberrantly expressed in multiple myeloma and promotes angiogenesis

(2013) K A Kocemba et al.   LEUKEMIA

MicroRNA-135b regulates metastasis suppressor 1 expression and promotes migration and invasion in colorectal cancer

(2013) Weiyun Wu et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Microenvironmental regulation of tumor progression and metastasis

(2013) Daniela F Quail et al.   NATURE MEDICINE

Upregulation of miR-135b Is Involved in the Impaired Osteogenic Differentiation of Mesenchymal Stem Cells Derived from Multiple Myeloma Patients

(2013) Song Xu et al.   PLoS One

MicroRNA-135b promotes lung cancer metastasis by regulating multiple targets in the Hippo pathway and LZTS1

(2013) Ching-Wen Lin et al.   Nature Communications

Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma

(2012) A. Chaidos et al.   BLOOD

Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features

(2012) A. K. Azab et al.   BLOOD

Hypoxic enhancement of exosome release by breast cancer cells

(2012) Hamish W King et al.   BMC CANCER

Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models

(2012) J. Hu et al.   Disease Models & Mechanisms

Leukemia cell to endothelial cell communication via exosomal miRNAs

(2012) T Umezu et al.   ONCOGENE

Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders

(2012) S Yoshizawa et al.   Blood Cancer Journal

miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma

(2011) H. Matsuyama et al.   BLOOD

Biological aspects of angiogenesis in multiple myeloma

(2011) Eléonore Otjacques et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma

(2011) S K Martin et al.   LEUKEMIA

Multiple Myeloma

(2011) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment of relapsed and refractory multiple myeloma in the era of novel agents

(2010) Niels W.C.J. van de Donk et al.   CANCER TREATMENT REVIEWS

The use of novel agents in the treatment of relapsed and refractory multiple myeloma

(2009) J P Laubach et al.   LEUKEMIA

Multiple myeloma

(2008) R. A. Kyle et al.   BLOOD

Detection and Specific Targeting of Hypoxic Regions within Solid Tumors: Current Preclinical and Clinical Strategies

(2008) M. Bache et al.   CURRENT MEDICINAL CHEMISTRY